Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 60,000 shares of the Company's common stock, effective as of December 2, 2024. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
旧金山，2024年12月3日（环球新闻）——Olema制药公司（“Olema”或“Olema肿瘤学”，纳斯达克：OLMA）是一家临床阶段的生物制药公司，专注于针对乳腺癌及其他疾病的靶向治疗的发现、开发和商业化。今日，公司宣布已向两名新员工授予购买公司普通股合计60,000股的期权，生效日期为2024年12月2日。这些奖励经过Olema董事会薪酬委员会的批准，并根据公司的2022年诱导计划提供，作为新员工入职Olema的诱导材料，符合纳斯达克上市规则5635(c)(4)。
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $10.21 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on December 2, 2024. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.
这些期权在四年内归属，第一年归属日期的25%将在该名员工的归属周年日归属，其余的将在接下来的三年中按36个月均等分期归属，前提是员工在这些归属日期时继续在Olema工作。这些期权的有效期为10年，行使价格为每股10.21美元，等于2024年12月2日公司普通股在纳斯达克上最后报告的交易价格。这些期权受Olema制药公司2022年诱导计划的条款约束。
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema根据纳斯达克上市规则5635(c)(4)提供此信息。
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at .
关于Olema肿瘤学
Olema肿瘤学是一家临床阶段的生物制药公司，致力于改变护理标准并改善生活在癌症中的女性的治疗结果。Olema通过深刻理解内分泌驱动的癌症、核受体及获得性抵抗机制，推动一系列新疗法的发展。我们的主要产品候选药物palazestrant (OP-1250)是一种专有的口服可用完全雌激素受体拮抗剂（CERAN）和选择性ER降解剂（SERD），目前正在进行一项名为OPERA-01的三期临床试验。此外，Olema还在开发一种有效的KAT6抑制剂（OP-3136）。Olema总部位于旧金山，在马萨诸塞州剑桥市设有业务。想要了解更多信息，请访问我们的网站。
Media and Investor Relations Contact
媒体和投资者关系联系人
Courtney O'Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
考特妮·奥科内克
企业通信副总裁
Olema肿瘤学
media@olema.com
